[go: up one dir, main page]

SG11201603131RA - Tau imaging probe - Google Patents

Tau imaging probe

Info

Publication number
SG11201603131RA
SG11201603131RA SG11201603131RA SG11201603131RA SG11201603131RA SG 11201603131R A SG11201603131R A SG 11201603131RA SG 11201603131R A SG11201603131R A SG 11201603131RA SG 11201603131R A SG11201603131R A SG 11201603131RA SG 11201603131R A SG11201603131R A SG 11201603131RA
Authority
SG
Singapore
Prior art keywords
imaging probe
tau imaging
tau
probe
imaging
Prior art date
Application number
SG11201603131RA
Inventor
Yukitsuka Kudo
Nobuyuki Okamura
Shozo Furumoto
Original Assignee
Clino Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clino Ltd filed Critical Clino Ltd
Publication of SG11201603131RA publication Critical patent/SG11201603131RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201603131RA 2013-10-22 2014-10-22 Tau imaging probe SG11201603131RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013233470 2013-10-22
PCT/JP2014/078146 WO2015060365A1 (en) 2013-10-22 2014-10-22 Tau imaging probe

Publications (1)

Publication Number Publication Date
SG11201603131RA true SG11201603131RA (en) 2016-05-30

Family

ID=52992954

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803294PA SG10201803294PA (en) 2013-10-22 2014-10-22 Tau imaging probe
SG11201603131RA SG11201603131RA (en) 2013-10-22 2014-10-22 Tau imaging probe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201803294PA SG10201803294PA (en) 2013-10-22 2014-10-22 Tau imaging probe

Country Status (13)

Country Link
US (1) US20160244411A1 (en)
EP (1) EP3061748A4 (en)
JP (1) JPWO2015060365A1 (en)
KR (1) KR20160072226A (en)
CN (1) CN105814023A (en)
AU (1) AU2014338155B2 (en)
BR (1) BR112016008871A8 (en)
CA (1) CA2928313A1 (en)
IL (1) IL245221A0 (en)
MX (1) MX2016005233A (en)
RU (1) RU2016119524A (en)
SG (2) SG10201803294PA (en)
WO (1) WO2015060365A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522414D0 (en) * 2015-12-18 2016-02-03 Clino Ltd Monoamine oxidase B binders
ES2846833T3 (en) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv PET imaging ligands
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
CN107488144B (en) * 2017-08-09 2021-06-04 复旦大学 Molecule capable of specifically binding and inhibiting Tau protein aggregation and preparation method and application thereof
JP7284490B2 (en) 2018-08-07 2023-05-31 国立大学法人東北大学 Monoamine oxidase B imaging probe
KR102344676B1 (en) 2020-02-12 2021-12-30 한국과학기술연구원 Novel compounds useful as near infrared fluorescent probes selectively binding to tau aggregates and preparation method thereof
KR20210128125A (en) * 2020-04-16 2021-10-26 연세대학교 산학협력단 A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising Quinoline Derivatives as Active Ingredients
KR102369838B1 (en) * 2020-04-16 2022-03-04 연세대학교 산학협력단 A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising Quinoline Derivatives as Active Ingredients
CN111892534A (en) * 2020-08-04 2020-11-06 中国科学技术大学 A pH-sensitive fluorescent probe, its preparation method and its application
CN113754583A (en) * 2021-09-03 2021-12-07 湖南工程学院 2- ([2, 2' -biquinolyl ] -3-ether) -1-ethanol and derivative and synthetic method thereof
CN113999172A (en) * 2021-11-17 2022-02-01 湖南工程学院 2- ((2-phenylquinoline-3-yl) ether) -1-ethanol and derivative and synthetic method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004054978A1 (en) * 2002-12-16 2006-04-20 株式会社 ビーエフ研究所 Quinoline derivatives as diagnostic probes for tau protein storage diseases
ES2797523T3 (en) 2009-03-23 2020-12-02 Lilly Co Eli Imaging agents to detect neurological disorders
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8483197B2 (en) * 2009-03-23 2013-07-09 Qualcomm Incorporated AP to legacy station SDMA protocol
KR101101977B1 (en) 2009-04-09 2012-01-02 (주)에스메디 2-arylnaphthalene, 2-arylquinoline derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for diagnosis or treatment of degenerative brain disease containing the same as an active ingredient
DK2634177T3 (en) * 2010-10-29 2016-08-15 Clino Ltd TAU IMAGE SOUND
US9040021B2 (en) * 2010-11-16 2015-05-26 Ge Healthcare Limited Heterocyclic compounds as imaging probes of tau pathology
GB201411571D0 (en) * 2014-06-30 2014-08-13 Ge Healthcare Ltd Radiolabelling method

Also Published As

Publication number Publication date
IL245221A0 (en) 2016-06-30
EP3061748A1 (en) 2016-08-31
KR20160072226A (en) 2016-06-22
WO2015060365A1 (en) 2015-04-30
CN105814023A (en) 2016-07-27
EP3061748A4 (en) 2017-04-05
RU2016119524A3 (en) 2018-06-14
BR112016008871A8 (en) 2020-03-24
US20160244411A1 (en) 2016-08-25
SG10201803294PA (en) 2018-06-28
RU2016119524A (en) 2017-11-28
MX2016005233A (en) 2017-01-05
AU2014338155B2 (en) 2018-08-23
AU2014338155A1 (en) 2016-05-19
CA2928313A1 (en) 2015-04-30
JPWO2015060365A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
GB201315248D0 (en) Imaging
IL240271A0 (en) Multiple-swath stripmap sar imaging
EP2951642A4 (en) OMNISTEREO IMAGING
GB201304149D0 (en) Ultrasound imaging
PT2846180T (en) Stereoscopic imaging device
EP3007435A4 (en) Solid state imaging apparatus
IL245221A0 (en) Tau imaging probe
EP3076432A4 (en) Imaging element
GB201318404D0 (en) An image sensor
SG11201507628WA (en) Medical imaging
EP2951582A4 (en) Testing device
EP3028622A4 (en) Imaging device
EP3077009A4 (en) Molecular imaging probes
GB2518957B (en) Imaging apparatus
EP2933672A4 (en) Imaging optics
EP3041214A4 (en) Imaging device
EP3021577A4 (en) Imaging device
EP3026489A4 (en) Imaging device
GB2510372B (en) Imaging sensor
EP2980838A4 (en) Probe device
GB2521888B (en) Ultrasound testing
PL2976637T3 (en) Testing device
GB201410076D0 (en) Testing device
EP2980561A4 (en) Imaging system
EP3000380A4 (en) Imaging device